Figure 1 (IMAGE) Impact Journals LLC Caption Figure 1: Elevated HDAC2 mRNA expression is poorly prognostic in DDLPS. (A) mRNA expression of HDAC2 and disease-free survival (DFS) data from 52 subjects with DDLPS from The Cancer Genome Atlas (TCGA) were split into two groups utilizing maximally selected rank statistic (Supplementary Figure 1A). Subjects with elevated HDAC2 expression experienced reduced DFS (median DFS: HDAC2 High 5.7 months, HDAC2 Low 31.1 months; HR 7.1, 95%CI 2.5-19.8, p < 0.001). (B) mRNA expression of HDAC2 and overall survival (OS) data from 58 subjects with DDLPS from the TCGA were split into two groups utilizing maximally selected rank statistics (Supplementary Figure 1A). Subjects with elevated HDCA2 expression experienced reduced OS (median OS: HDAC2 High 18.5 months, HDAC2 Low 76.4 months; HR 4.4, 95%CI 1.1-21.9, p = 0.04). (C) mRNA expression of HDAC2 and distant recurrence-free survival (DRFS) data from 40 subjects with DDLPS from the Memorial Sloan-Kettering Cancer Center Dataset (MSKCC) were split into two utilizing maximally selected rank statistic (Supplementary Figure 1B). Subjects with elevated HDAC2 expression experienced reduced DRFS (median DRFS: HDAC2 High 8.3 months, HDAC2 Low not met; HR 2.8, 95%CI 1.2-6.4, p = 0.02). Credit James L. Chen, email: James.Chen@osumc.edu Usage Restrictions CCBY License Licensed content Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.